BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ceccarelli V, Barchetta I, Cimini FA, Bertoccini L, Chiappetta C, Capoccia D, Carletti R, Di Cristofano C, Silecchia G, Fontana M, Leonetti F, Lenzi A, Baroni MG, Barone E, Cavallo MG. Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. Int J Mol Sci 2020;21:E9091. [PMID: 33260451 DOI: 10.3390/ijms21239091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Mancuso C. Biliverdin reductase as a target in drug research and development: Facts and hypotheses. Free Radic Biol Med 2021;172:521-9. [PMID: 34224815 DOI: 10.1016/j.freeradbiomed.2021.06.034] [Reference Citation Analysis]
2 Cimini FA, Perluigi M, Barchetta I, Cavallo MG, Barone E. Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. Int J Mol Sci 2022;23:5574. [PMID: 35628384 DOI: 10.3390/ijms23105574] [Reference Citation Analysis]
3 Cimini FA, Barchetta I, Zuliani I, Pagnotta S, Bertoccini L, Dule S, Zampieri M, Reale A, Baroni MG, Cavallo MG, Barone E. Biliverdin reductase-A protein levels are reduced in type 2 diabetes and are associated with poor glycometabolic control. Life Sci 2021;284:119913. [PMID: 34453944 DOI: 10.1016/j.lfs.2021.119913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang X, Li J, Liu T, Zhao M, Liang B, Chen H, Zhang Z, Bukhari I. Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/4369329] [Reference Citation Analysis]
5 Thomas DT, Delcimmuto NR, Flack KD, Stec DE, Hinds TD. Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin. Antioxidants 2022;11:179. [DOI: 10.3390/antiox11020179] [Reference Citation Analysis]
6 Yaqub S, Ananias P, Shah A, Luenam K, Jose AM, Melo JP, Turkistani A, Mohammed L. Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review. Cureus 2021;13:e18201. [PMID: 34722019 DOI: 10.7759/cureus.18201] [Reference Citation Analysis]
7 Ryter SW. Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders. Antioxidants 2022;11:555. [DOI: 10.3390/antiox11030555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 McClung JA, Levy L, Garcia V, Stec DE, Peterson SJ, Abraham NG. Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications. Pharmacol Ther 2021;:107975. [PMID: 34499923 DOI: 10.1016/j.pharmthera.2021.107975] [Reference Citation Analysis]
9 Barone E, Di Domenico F, Perluigi M, Butterfield DA. The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med 2021;176:16-33. [PMID: 34530075 DOI: 10.1016/j.freeradbiomed.2021.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]